Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Geffriaud

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Nephrology|September 1, 1992
Decrease of tumor-like calcification in uremia despite aggravation of secondary hyperparathyroidism: a case reportC Geffriaud, E Allinne, B Page, et al.
Kidney International|July 1, 1994
Isotype and affinity of anti-myeloperoxidase autoantibodies in systemic vasculitisE Kokolina, L H Noël, P Nusbaum, et al.
Presse Medicale (Paris, France : 1983)|December 10, 1988
[Ankylosing spondylitis with type AA amyloidosis. 6 cases]C Geffriaud, L H Noël, P Blanche, et al.
Gastroenterologie Clinique Et Biologique|May 1, 1988
[Hepatic involvement in HIV 1 virus infection]C Geffriaud, T Poynard, J F Delfraissy, et al.
Nephrologie|January 1, 1996
[Demography and effects of chronic renal insufficiency in Ile-de-France]P Jungers, E Giraud, P Chauveau, et al.
European Urology|February 21, 1998
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flowW P Witjes, J J de la Rosette, M Zerbib, et al.
Advances in Nephrology From the Necker Hospital|January 1, 1993
Antineutrophil cytoplasm antibodies: diversity and clinical applicationsL H Noël, C Geffriaud, D Chauveau, et al.
European Urology|September 10, 1998
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study GroupF M Debruyne, A Jardin, D Colloi, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Nephrology|September 1, 1992
Decrease of tumor-like calcification in uremia despite aggravation of secondary hyperparathyroidism: a case reportC Geffriaud, E Allinne, B Page, et al.
Kidney International|July 1, 1994
Isotype and affinity of anti-myeloperoxidase autoantibodies in systemic vasculitisE Kokolina, L H Noël, P Nusbaum, et al.
Presse Medicale (Paris, France : 1983)|December 10, 1988
[Ankylosing spondylitis with type AA amyloidosis. 6 cases]C Geffriaud, L H Noël, P Blanche, et al.
Gastroenterologie Clinique Et Biologique|May 1, 1988
[Hepatic involvement in HIV 1 virus infection]C Geffriaud, T Poynard, J F Delfraissy, et al.
Nephrologie|January 1, 1996
[Demography and effects of chronic renal insufficiency in Ile-de-France]P Jungers, E Giraud, P Chauveau, et al.
European Urology|February 21, 1998
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flowW P Witjes, J J de la Rosette, M Zerbib, et al.
Advances in Nephrology From the Necker Hospital|January 1, 1993
Antineutrophil cytoplasm antibodies: diversity and clinical applicationsL H Noël, C Geffriaud, D Chauveau, et al.
European Urology|September 10, 1998
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study GroupF M Debruyne, A Jardin, D Colloi, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Pageof 2